Hanoch Rappaport
Amministratore Delegato presso Provident Fund of the Hebrew University of Jerusalem Ltd.
Profilo
Hanoch Rappaport is currently the Chief Executive Officer at Provident Co. of the Employees of the Hebrew University Ltd.
since 2014.
He is also currently serving as the Chief Financial Officer-Employees Provident Fund at The Hebrew University of Jerusalem.
Previously, he held positions as a Director at Anchiano Therapeutics Ltd., BioCancell Therapeutics, Inc., and Bank Hapoalim BM.
He also worked as an Investment Manager at A.
Heifetz & Co. Mr. Rappaport has a Master's in Business Administration from Tel-Aviv University and The Hebrew University of Jerusalem, as well as an undergraduate degree from Bar-Ilan University.
Posizioni attive di Hanoch Rappaport
| Società | Posizione | Inizio |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
| Provident Fund of the Hebrew University of Jerusalem Ltd. | Amministratore Delegato | 01/01/2014 |
Precedenti posizioni note di Hanoch Rappaport
| Società | Posizione | Fine |
|---|---|---|
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Direttore/Membro del Consiglio | 01/11/2013 |
| ANCHIANO THERAPEUTICS LTD. | Direttore/Membro del Consiglio | - |
| A. Heifetz & Co. | Direttore degli Investimenti | - |
| BANK HAPOALIM B.M. | Corporate Officer/Principal | - |
Formazione di Hanoch Rappaport
| Tel-Aviv University | Masters Business Admin |
| The Hebrew University of Jerusalem | Masters Business Admin |
| Bar-Ilan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BANK HAPOALIM B.M. | Finance |
| Aziende private | 4 |
|---|---|
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | Health Technology |
| A. Heifetz & Co. | |
| Provident Fund of the Hebrew University of Jerusalem Ltd. | Finance |
- Borsa valori
- Insiders
- Hanoch Rappaport